健脾解毒汤联合化疗治疗胃癌肝转移随机平行对照研究  

Random Parallel Control Study of Jianpi Jiedu Tang(健脾解毒汤)Plus Chemotherapy in the Treatment of Liver Metastatic Gastric Cancer

作　　者：袁旭[1] 梁芳[1] 许建华[1] 孙珏[1] 张勇[1] 李萍[1] 

机构地区：[1]上海中医药大学附属普陀医院中医肿瘤科,上海200062

出　　处：《实用中医内科杂志》2016年第9期45-49,共5页Journal of Practical Traditional Chinese Internal Medicine

基　　金：普陀医院院级育英人才培养计划(No:2013SR129I)~~

摘　　要：[目的]观察健脾解毒汤联合化疗治疗胃癌肝转移疗效。[方法]使用随机平行对照方法,将62例住院患者按病志号抽签方法简单随机分两组。对照组30例奥沙利铂(130mg/m^2)d1+替吉奥(60mg/m^2)d1-14方案连续化疗。治疗组32例健脾解毒汤(生黄芪15g,白术12g,猪苓15g,薏苡仁30g,八月札15g,石见穿、野葡萄藤各30g),1剂/d,水煎200m L,早晚口服;化疗方案同对照组。连续治疗21d为1疗程。观测临床症状、生存质量、毒副反应、中医证候疗效指数、CD3^+、CD4^+、CD8^+。连续治疗2疗程,判定疗效。[结果]有效率、疾病控制率、中位无进展生存期两组间无明显差异(P>0.05),1年生存率治疗组优于对照组(P<0.05)。临床受益率治疗组优于对照组(P<0.05)。KPS受益率、疼痛受益率两组间无明显差异(P>0.05),体质量受益率治疗组优于对照组(P<0.05)。神经毒性、乏力方面治疗组明显低于对照组(P<0.05),其他不良反应两组间无明显差异(P>0.05)。中医证候疗效指数治疗组优于对照组(P<0.05)。CD3^+、CD4^+、CD8^+两组间无明显差异(P>0.05),NK治疗组优于对照组(P<0.05)。[结论]健脾解毒汤联合化疗治疗胃癌肝转移,疗效满意,无严重不良反应,值得推广。[Objective] To observe the curative effect of Jianpi Jiedu Tang plus chemotherapy in the treatment of liver metastatic gastric cancer. [Methods] Using randomized controlled method, 62 patients in hospital were randomly divided into 2 groups according to the medical record number draw method. The control group （30 patients） used continuous treatment chemotherapy regimens （oxaliplatin130 mg/m2dl＋Tegafur Gimeracil Oteracil Potassium Capsule 60 mg/m2dl-14）. The treatment group （32 patients） used Jianpi Jiedu Decoction （membranaceus 15 g, macrocephalia 12 g, grifola 15 g, semen coicis 30 g, Fructus Akebiae 15g, Salvia chinensis 30 g, hairy grape stem 30 g, decoction, 200 mL/times, 2 times a day, breakfast and dinner the night before oral）. The chemotherapy regimens were same as the control group. Continuous treatment of 21 days was a period of treatment. Observe clinical symptoms, quality of survival, adverse reaction, Chinese medicine syndrome curative effect index, immunity index, side effect. [Results] Effect rate, disease control rate, the median progression-free surial had no obvious difference between the two groups （P〉0.05）. 1 year survival rate was higher in the treatment group than in the control group （P〈0.05）. Clinical benefit rate was higher in the treatment group than in the control group （P 〈0.05）. KPS benefit rate, pain benefit rate had no obvious difference between the two groups （P〉0.05）. Weight benefit rate was higher in the treatment group than in the control group （P〈O.05）. Neurotoxicity and fatigue were lower in the treatment group than in the control group （P〈0.05）. Other adverse reactions had no obvious difference between the two groups （P〉0.05）. Chinese medicine syndrome curative effect index was higher in the treatment group than in the control group （P〈0.05）. The number of CD3^＋、CD4^＋、CD8^＋ had no obvious difference between the two groups （P〉0.05）. The number of NK was higher in the treatment group than in the c

关 键 词：胃癌肝转移 症瘕 健脾解毒汤 奥沙利铂 替吉奥 生存质量 毒副反应 中医证候疗效指数 CD3^+、CD4^+、CD8^+ 中西医结合治疗 随机平行对照研究 

分 类 号：R273.52[医药卫生—中西医结合]